United States-based Pfizer is opening a new manufacturing facility in Andover, Massachusetts, it was reported yesterday.
The facility covers a 175,000 square-foot area. It accommodates commercial manufacturing and product development functions for the development and production of complex biologics and vaccines. The site will offer 75 new jobs for the Andover area economy, adding to the around 2,000 staff currently based in Massachusetts.
The newly opened Andover Clinical Manufacturing Facility will expand the capacity for Pfizer's BioTherapeutics Pharmaceutical Sciences organization to manufacture clinical supplies. The company's ACMF investment is more than USD200m and includes five independent manufacturing suites, with more than 50 projects currently in development.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine